Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cherney

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Canadian Journal of Diabetes|April 14, 2018
Chronic Kidney Disease in Diabetes, Philip McFarlane, David Cherney, et al.
Kidney Medicine|August 1, 2020
Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor TherapyHannes Neuwirt, Andrea Burtscher, David Cherney, et al.
European Journal of Internal Medicine|April 12, 2023
Tirzepatide decreases systolic and diastolic blood pressureSidar Copur, Atalay Demiray, David Cherney, et al.
Journal of Diabetes and Its Complications|July 15, 2022
Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk enginesElisabeth B Stougaard, Peter Rossing, David Cherney, et al.
Journal of the American Society of Nephrology : JASN|September 17, 2025
Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered QuestionsHiddo J L Heerspink, Petter Bjornstad, David Cherney, et al.
Nature Reviews. Nephrology|January 12, 2026
Next-generation therapeutics for diabetic kidney diseaseTae Won Yi, Vikas S Sridhar, Jennifer Scott, et al.
Journal of Market Access & Health Policy|August 28, 2024
Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect ComparisonDavid Cherney, Kerstin Folkerts, Paul Mernagh, et al.
Plos One|October 31, 2017
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteomeDavid Cherney, Bruce A Perkins, Yuliya Lytvyn, et al.
Cardiorenal Medicine|December 17, 2025
The Role of Inflammation and High-Sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: the FLAME-ASCVD Survey Among NephrologistsVlado Perkovic, David Cherney, Edmundo Erazo-Tapia, et al.
Cardiorenal Medicine|January 31, 2019
Biomarkers of Inflammation, Fibrosis, and Acute Kidney Injury in Patients with Heart Failure with and without Left Ventricular Assist Device ImplantationLiza Grosman-Rimon, Sarah Genevieve Hui, Danit Freedman, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Canadian Journal of Diabetes|April 14, 2018
Chronic Kidney Disease in Diabetes, Philip McFarlane, David Cherney, et al.
Kidney Medicine|August 1, 2020
Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor TherapyHannes Neuwirt, Andrea Burtscher, David Cherney, et al.
European Journal of Internal Medicine|April 12, 2023
Tirzepatide decreases systolic and diastolic blood pressureSidar Copur, Atalay Demiray, David Cherney, et al.
Journal of Diabetes and Its Complications|July 15, 2022
Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk enginesElisabeth B Stougaard, Peter Rossing, David Cherney, et al.
Journal of the American Society of Nephrology : JASN|September 17, 2025
Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered QuestionsHiddo J L Heerspink, Petter Bjornstad, David Cherney, et al.
Nature Reviews. Nephrology|January 12, 2026
Next-generation therapeutics for diabetic kidney diseaseTae Won Yi, Vikas S Sridhar, Jennifer Scott, et al.
Journal of Market Access & Health Policy|August 28, 2024
Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect ComparisonDavid Cherney, Kerstin Folkerts, Paul Mernagh, et al.
Plos One|October 31, 2017
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteomeDavid Cherney, Bruce A Perkins, Yuliya Lytvyn, et al.
Cardiorenal Medicine|December 17, 2025
The Role of Inflammation and High-Sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: the FLAME-ASCVD Survey Among NephrologistsVlado Perkovic, David Cherney, Edmundo Erazo-Tapia, et al.
Cardiorenal Medicine|January 31, 2019
Biomarkers of Inflammation, Fibrosis, and Acute Kidney Injury in Patients with Heart Failure with and without Left Ventricular Assist Device ImplantationLiza Grosman-Rimon, Sarah Genevieve Hui, Danit Freedman, et al.
Pageof 6